Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06256588 · ClinicalTrials.gov registry record · Phase 3

A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

A Phase 3 study of Neoplasms, Head and Neck, sponsored by GlaxoSmithKline.

Recruiting
Registry status
Phase 3
Development phase
864
Enrollment target
20
Study locations

NCT06256588 is a Phase 3 study of Neoplasms, Head and Neck that is actively recruiting participants, run by GlaxoSmithKline. The registered enrollment target is 864 participants, above the 194-participant average among 4 other Neoplasms, Head and Neck trials with a reported enrollment target (345% higher). The trial reports 20 study locations across 15 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06256588, a Phase 3 study of Neoplasms, Head and Neck, is actively recruiting participants, sponsored by GlaxoSmithKline.

RECRUITING
Registry status
Phase 3
Development phase
864 participants
Enrollment target
20
Study locations

Study Summary

The goal of this study is to assess the safety and effectiveness of Dostarlimab compared to Placebo in adult participants with Head and Neck Squamous Cell Carcinoma (HNSCC)

Conditions Studied

Neoplasms, Head and Neck

Interventions

  • DRUG Placebo
  • DRUG Dostarlimab

Study Locations (20)

California

  • GSK Investigational Site - Los Angeles
  • GSK Investigational Site - Solvang
  • GSK Investigational Site - Stockton
  • GSK Investigational Site - Torrance

Connecticut

  • GSK Investigational Site - Farmington
  • GSK Investigational Site - New Haven

Florida

  • GSK Investigational Site - St. Petersburg
  • GSK Investigational Site - Tamarac

Arkansas

  • GSK Investigational Site - Jonesboro

District of Columbia

  • GSK Investigational Site - Washington D.C.

Georgia

  • GSK Investigational Site - Atlanta

Indiana

  • GSK Investigational Site - Fort Wayne

Iowa

  • GSK Investigational Site - Iowa City

Trial Details

FieldValue
Enrollment Target 864 participants
Start Date 2024-03-21
Est. Completion 2029-10-26
Phase Phase 3

Sponsor

GlaxoSmithKline

1,345 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06256588

The ClinicalTrials.gov registry entry for NCT06256588 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 864 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 194-participant average among 4 other Neoplasms, Head and Neck trials with a reported enrollment target (345% higher). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Neoplasms, Head and Neck appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06256588 reports 20 study locations spanning 15 distinct geographic areas - top geographies include California, Connecticut, Florida.

Frequently Asked Questions

What is clinical trial NCT06256588 about?

NCT06256588 is a clinical study titled "A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma". The goal of this study is to assess the safety and effectiveness of Dostarlimab compared to Placebo in adult participants with Head and Neck Squamous Cell Carcinoma (HNSCC)

What is the current status of trial NCT06256588?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 864 participants. The study started on 2024-03-21. Estimated completion is 2029-10-26.

What conditions does trial NCT06256588 study?

This clinical trial studies the following conditions: Neoplasms, Head and Neck.

What interventions are being tested in trial NCT06256588?

The interventions under investigation include: Placebo (DRUG), Dostarlimab (DRUG).

Who is sponsoring clinical trial NCT06256588?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06256588 being conducted?

This trial has 20 study locations across Arkansas, California, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Neoplasms, Head and Neck

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Neoplasms, Head and Neck

All registered trials for this condition

Arkansas

All trials with a study site in Arkansas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.